TY - JOUR
T1 - Modern radiotherapy for a medieval malady
T2 - An analysis of treatment toxicities for locally advanced head and neck cancers
AU - Almas, Fathima
AU - Singh, Anshul
AU - Sharan, Krishna
AU - Lewis, Shirley
AU - Reddy, Sannareddy Anusha
AU - Velu, Umesh
AU - Augustine, Priyanka
N1 - Publisher Copyright:
© 2021, Shriaz University of Medical Sciences. All rights reserved.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Background: Concurrent chemo-radiation has proven to be beneficial in a majority of patients with locally advanced head and neck cancers. Despite modern techniques of radiation delivery, the trade-off is acute and entails late toxicities for a considerable number of patients. Very few studies have reported the outcomes of these patients. We aimed to prospectively assess and report the toxicities of patients undergoing definitive chemo-radiation by the volumetric modulated arc therapy (VMAT) for the treatment of advanced laryngeal and hypopharyngeal cancer. Method: This prospective observational study was conducted in a single tertiary care center over a period of two years. We recorded acute and late toxicities during and after the treatment of patients with locally advanced laryngeal and hypopharyngeal cancer treated with definitive chemo-radiotherapy using VMAT. Chi square test and Fisher’s exact test were used for comparing the significance of outcome parameters with different variables. Results: 28 patients who met the inclusion criteria were taken up for analysis. The median age was 59 years. The median treatment time was 48 days. The mean dose to parotid, superior, and mid constrictors was 32, 45, and 64 Grays (Gy). At completion, 7% of the patients had grade 3 or more dermatitis, 4% had grade 3 or higher mucositis, and no patient had grade 3 or higher xerostomia. Five patients treated for hypopharynx cancer developed strictures. Conclusion: Our results showed that concurrent chemo-radiotherapy using VMAT is a promising method of treatment for advanced laryngeal and hypopharyngeal squamous cell cancer with an acceptable toxicity profile.
AB - Background: Concurrent chemo-radiation has proven to be beneficial in a majority of patients with locally advanced head and neck cancers. Despite modern techniques of radiation delivery, the trade-off is acute and entails late toxicities for a considerable number of patients. Very few studies have reported the outcomes of these patients. We aimed to prospectively assess and report the toxicities of patients undergoing definitive chemo-radiation by the volumetric modulated arc therapy (VMAT) for the treatment of advanced laryngeal and hypopharyngeal cancer. Method: This prospective observational study was conducted in a single tertiary care center over a period of two years. We recorded acute and late toxicities during and after the treatment of patients with locally advanced laryngeal and hypopharyngeal cancer treated with definitive chemo-radiotherapy using VMAT. Chi square test and Fisher’s exact test were used for comparing the significance of outcome parameters with different variables. Results: 28 patients who met the inclusion criteria were taken up for analysis. The median age was 59 years. The median treatment time was 48 days. The mean dose to parotid, superior, and mid constrictors was 32, 45, and 64 Grays (Gy). At completion, 7% of the patients had grade 3 or more dermatitis, 4% had grade 3 or higher mucositis, and no patient had grade 3 or higher xerostomia. Five patients treated for hypopharynx cancer developed strictures. Conclusion: Our results showed that concurrent chemo-radiotherapy using VMAT is a promising method of treatment for advanced laryngeal and hypopharyngeal squamous cell cancer with an acceptable toxicity profile.
UR - http://www.scopus.com/inward/record.url?scp=85119906841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119906841&partnerID=8YFLogxK
U2 - 10.30476/mejc.2021.84516.1235
DO - 10.30476/mejc.2021.84516.1235
M3 - Article
AN - SCOPUS:85119906841
SN - 2008-6709
VL - 12
SP - 527
EP - 534
JO - Middle East Journal of Cancer
JF - Middle East Journal of Cancer
IS - 4
ER -